Dainippon Sumitomo To Continue Alone After Joint Development With Chugai Ends For Cancer Peptide Vaccines
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo and Chugai will terminate a joint development agreement regarding cancer peptide vaccines WT4869 and WT2725, the companies announced April 8.